Explore our top-tier synthesized therapeutic APIs manufactured under stringent purity controls, available for pilot validation, clinical development, and commercial supply.
The global peptide therapeutics sector is experiencing unprecedented capital injection and structural re-engineering, propelled by incretin mimetics (GLP-1, GIP, Glucagon receptor agonists), targeted oncology, and gut microbiome regulators.
The global commercialization of multivalent GLP-1/GIP agonists for obesity and type-2 diabetes mellitus (such as Semaglutide, Tirzepatide, and Survodutide) has caused an acute upstream capacity crunch. Sourcing executives now evaluate suppliers on unbroken tonnage delivery, raw material security, and the capability to synthesize extended 30-40 amino acid chains with complex lipid side-chains.
While recombinant DNA fermentation processes historically supported select early peptide APIs, modern chemical Hybrid Solid-Phase / Liquid-Phase Synthesis (SPPS/LPPS) dominates current commercial filings. Chemical synthesis eliminates host-cell proteins (HCP) and endotoxin contamination risks while offering unrivaled flexibility for unnatural, D-amino acid, and cyclic modifications.
Global health authorities (US FDA, EMA, NMPA) demand rigorous profiling for peptide drug substances. Critical quality parameters require precise isolation of D-enantiomers, truncation fragments, beta-isomers, and deletion peptides down to < 0.10% identification thresholds, mandating state-of-the-art prep-HPLC purification and orthogonal HRMS analysis.
Thinheal operates an open and audit-ready commercial framework. Pricing parameters are dynamically determined by synthesis cycle complexity, stereochemical stability, purification runs, and target regulatory tier.
| Peptide API Substance | CAS Number | Clinical / Target Indication | Synthesis Technology | Standard Purity (HPLC) | Procurement Tier & Commercial Scope |
|---|---|---|---|---|---|
| Semaglutide API | 910463-68-2 | T2DM, Chronic Weight Management, MASH | Sequential SPPS + Automated Chemo-Cleavage | ≥ 99.5% (Single max imp < 0.5%) | Gram scale to 100+ kg multi-ton campaigns |
| Retatrutide API | 2381089-83-2 | Triple GIP/GLP-1/Glucagon Receptor Agonist | Multi-Fragment Condensation / SPPS | ≥ 99.0% (Single max imp < 0.8%) | Custom R&D batches, Pilot scale, Commercial DMF |
| Survodutide API | 2805997-46-8 | Dual GLP-1/Glucagon Agonist, Fibrosis | Advanced Solid-Phase Peptide Synthesis | ≥ 99.2% (Mass spectrometry confirmed) | Process validation lots & scale-up programs |
| Linaclotide API | 851199-59-2 | IBS-C, Chronic Idiopathic Constipation | Directional 3-Disulfide Bond Folding Strategy | ≥ 98.5% (Native isomer purity) | Gram lots to multi-kilogram cGMP batches |
| Teduglutide API | 287714-30-1 | Short Bowel Syndrome (GLP-2 Analogue) | Solid-Phase Peptide Elongation | ≥ 99.0% (Endotoxin < 10 EU/mg) | Pre-clinical through to commercial generic dossiers |
| Vasopressin API | 50-57-7 | Vasodilatory Shock, Diabetes Insipidus | Disulfide Cyclization SPPS Chemistry | ≥ 99.0% (Ph. Eur. / USP compliant) | Immediate commercial inventory, ton-level capacity |
| BPC-157 Pentadecapeptide | 137525-51-0 | Cytoprotective Tissue Regeneration | Automated Liquid / Solid Coupling | ≥ 99.0% (Residual TFA < 1.0% or Acetate) | Bulk cosmetic / regenerative therapeutic supply |
| Copper Tripeptide (GHK-Cu) | 89030-95-5 | Dermatological Synthesis, Skin Remodeling | High-throughput Liquid Phase Coordination | ≥ 99.0% (Cu content stoich. verified) | Multi-ton industrial cosmetics batch availability |
* Tiered pricing structures available under non-disclosure agreements (NDAs) based on cumulative project commitment and technical requirements.
Overcoming manufacturing bottlenecks in long-chain and structurally complex peptide APIs requires replacing legacy methodologies with automated, environmentally sound chemical engineering.
Complex folded peptides like Linaclotide require three distinct intramolecular disulfide bonds. Our orthogonal protecting group strategy (Trt, Acm, Mob) eliminates random misfolding, increasing target regioisomer yields by up to 34% compared to open-air random oxidation.
By integrating continuous flow microreactors into the elongation phase, amino acid coupling times are condensed from hours to minutes. Real-time UV-absorption feedback detects aggregated domains during GLP-1 peptide backbone growth, maintaining near 99% crude purities.
Transitioning from hazardous solvents toward environmentally benign alternatives (2-MeTHF, Cyrene) has significantly reduced Thinheal’s Process Mass Intensity (PMI). In-house closed-loop solvent recovery units recapture > 85% of solvents across all commercial synthesis lines.
Our dual preparative reverse-phase HPLC skids paired with pilot-to-production industrial freeze dryers (lyophilizers) guarantee fine cake structure, rapid reconstitution, tight residual water control (< 3.0%), and low counter-ion variance (Acetate/TFA balance).
Securing an active pharmaceutical ingredient goes far beyond initial synthesis. Thinheal supports your program through every stage of regulatory filing and cold-chain distribution worldwide.
With dedicated desks for North America, Europe, Russia/CIS, and the Middle East, our technical teams provide localized account management, multi-lingual consultations, and immediate technical reviews to keep your sourcing timelines on track.
We prepare comprehensive Drug Master Files (DMF), Certificates of Suitability (CEP), and Common Technical Document (CTD) Module 3 packages. Complete documentation covers route justification, starting material qualification, and analytical method validation (ICH Q2(R1)).
Lyophilized peptides require strict temperature management to prevent hydrolytic degradation. Every international shipment is packaged with calibrated vacuum insulation panels, data loggers (-20°C or -80°C dry ice), and validated international freight routes.
Direct answers to the questions sourcing managers, formulation directors, and quality auditors ask us prior to technical onboarding.
Thinheal operates an integrated synthesis base in Hangzhou featuring multi-ton total capacity for chemically synthesized peptides. Individual batch capabilities range from pilot runs of 100g up to single-campaign outputs exceeding 50kg, supported by large-aperture preparative HPLC systems.
We employ advanced Chiral Amino Acid Analysis (C-AAA) via gas chromatography-mass spectrometry (GC-MS) following complete acid hydrolysis. This precisely quantifies racemization levels for every amino acid residue, ensuring total D-amino acid impurities remain well below strict compendial thresholds.
Yes. While trifluoroacetic acid (TFA) is the standard cleavage ion pair in reverse-phase HPLC, we provide ion-exchange chromatography to convert TFA salts to pharmaceutical-grade acetate, hydrochloride, or other specific salt forms, verifying residual TFA at < 0.1% via fluoride-selective electrode or IC analysis.
Every batch includes a lot-specific Certificate of Analysis (CoA) containing reverse-phase HPLC purity chromatograms, electrospray ionization mass spectrometry (ESI-MS/HRMS), amino acid analysis (AAA), residual water content (Karl Fischer), counter-ion assay, bacterial endotoxin testing, and residual solvent analysis (GC-HS).
Our contract research team evaluates sequence complexity, propensity for aggregation, and potential side reactions. We then engineer custom segment condensation pathways or modified coupling protocols (microwave-assisted or continuous flow) to improve synthesis yields on complex target sequences.
Standard catalog APIs with ready inventory can be dispatched within 48 to 72 hours via cold-chain transit. Custom synthesis, route development, and pilot batches typically require 3 to 6 weeks, depending on chain length, secondary modifications, and analytical validation requirements.
Supplying multi-kilo volumes of neuroactive, metabolic, tissue repair, and high-purity cosmetic peptides manufactured under strict batch controls.
Whether you are preparing an IND submission, requiring pilot-scale process validation, or securing multi-ton commercial API inventory, our technical specialists and chemistry teams are ready to support your program.
Thin
